ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.International journal of cancer · 2026Review
- The research progress of gastric cancer vaccines: a narrative review.Translational cancer research · 2026Review
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Targeted DDR1 Treatment Strategy Enhances PD-1 Immunotherapy Efficacy against Gastric Cancer.Journal of medicinal chemistry · 2025Article
- Intravenous iRGD-Guided, RBC-Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD-1 Blockade.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Materials today. Bio · 2025Review
- Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Intranodal injection of neoantigen-bearing engineeredActa pharmaceutica Sinica. B · 2025Article
- Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025Review
- Thylakoids for enhanced photodynamic therapy in hypoxic tumours.Science and technology of advanced materials · 2025Review
- Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025Review
- Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design.Human vaccines & immunotherapeutics · 2024Article
- Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.Human vaccines & immunotherapeutics · 2024Article
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Current status of vaccine immunotherapy for gastrointestinal cancers.Surgery today · 2024Review
- Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.Nanoscale · 2024Review
- Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.Clinical and experimental medicine · 2024Review
- A Thermosensitive Bi-Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti-Tumor Efficacy of Frameshift Neoantigens.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for adjuvant cancer immunotherapy is generated. PNVAC triggers superior protective efficacy against tumor recurrence and promotes longer survival than free neoantigens, especially when combined with anti-PD-1 treatment in a murine tumor model. A phase I clinical trial (ChiCTR1800017319) is initiated to evaluate the safety, immunogenicity, and prophylactic effect of PNVAC on preventing tumor recurrence in patients with high-risk gastric/gastroesophageal junction cancer after adjuvant chemotherapy of postsurgical resection. The one- and two-year disease-free survival rates are significantly higher than historical record. PNVAC induces both CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.